價格 | ¥148 | ¥322 | ¥429 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 Cerdulatinib hydrochloride | 英文名稱:Cerdulatinib hydrochloride |
CAS:1369761-01-2 | 品牌: TargetMol |
產地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.23% | 產品類別: 抑制劑 |
貨號: T6104 |
名稱 | Cerdulatinib hydrochloride |
描述 | Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM. |
細胞實驗 | Cell lines (Ramos RA-1, Daudi, Toledo, SU-DHL4 and SU-DHL6) are cultured in RPMI media supplemented with 10% fetal bovine serum. Cells are treated with the indicated concentrations of PRT062070, the SYK-selective inhibitor PRT060318, the pan-JAK inhibitor 1, a 1:1 combination of PRT060318 and JAK inhibitor 1, or vehicle control (0.5% dimethylsulfoxide) for 72 hours. Cell viability assays are performed using CellTiter Glo in 384-well plates. Cells are seeded at a density of 5000 cells per well. (Only for Reference) |
激酶實驗 | Purified Kinase Assays: Potency against purified SYK is determined by fluorescence resonance energy transfer. A broader panel of 270 purified kinases is surveyed in which PRT062070 is tested at a fixed concentration of 300 nM. [33P]-labeled substrate is measured after incubation of purified kinase with peptide substrate and [33P]ATP at the Km concentration for the kinase. |
體外活性 | In human whole blood from normal donors, Cerdulatinib affects BCR-mediated B-cell activation by dual inhibition of SYK and JAK. As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduces cell viability in a subset of NHL cell lines, and induces apoptosis in BCR-signaling competent NHL cell lines. [1] |
體內活性 | In a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg p.o.) significantly improves inflammatory infiltrate within the synovium and the integrity of the articular cartilage. In addition, Cerdulatinib also blocks BCR-induced B-cell activation and splenomegaly in mice. [1] |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 4.82 mg/mL (10 mM), Sonication is recommended. |
關鍵字 | Inhibitor | malignancies | Tyk2 | PRT-2070 | PRT-062070 Hydrochloride | Cerdulatinib hydrochloride | PRT 062070 Hydrochloride | PRT-2070 Hydrochloride | PRT 2070 Hydrochloride | PRT062070 Hydrochloride | Janus kinase | PRT2070 Hydrochloride | JAK | Syk | Cerdulatinib Hydrochloride | autoimmune | dual | PRT 062070 | B-cell | PRT-062070 | Spleen tyrosine kinase | PRT 2070 | inhibit |
相關產品 | JAK-IN-10 | Tofacitinib Citrate | Deucravacitinib | Gefitinib | ANTHRAQUINONE-2-CARBOXYLIC ACID | Pexidartinib | Baricitinib | PLX5622 | Fedratinib | Ruxolitinib phosphate | Ibrutinib | Delgocitinib |
相關庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經典已知活性庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 膜蛋白靶向化合物庫 | 藥物功能重定位化合物庫 | 酪氨酸激酶分子庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產物,生化試劑,分子生物學,分子砌塊,生物技術服務 | 經營模式 | 貿易,工廠,試劑,定制,服務 |
產品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP6年
|
成都彼樣生物科技有限公司
|
2025-02-08 | |
詢價 |
VIP4年
|
上海海皋科技有限公司
|
2024-12-16 | |
¥329.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |